{"disease":{"id":"primary-mediastinal-b-cell-lymphoma-pmbcl","name":"primary mediastinal b cell lymphoma pmbcl"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06339255","title":"Italian Observational Study on CAR-T Therapy for Lymphoma","phase":"","overall_status":"RECRUITING","enrollment_count":5300,"lead_sponsor_name":"Paolo Corradini","has_results":false},{"nct_id":"NCT05162170","title":"Primary Mediastinal Large B-cell Lymphoma (PMBCL): Multicenter Retrospective Study","phase":"","overall_status":"COMPLETED","enrollment_count":633,"lead_sponsor_name":"Fondazione Italiana Linfomi - ETS","has_results":false},{"nct_id":"NCT05934084","title":"Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors","phase":"NA","overall_status":"RECRUITING","enrollment_count":552,"lead_sponsor_name":"Fondazione Italiana Linfomi - ETS","has_results":false},{"nct_id":"NCT02348216","title":"Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":307,"lead_sponsor_name":"Kite, A Gilead Company","has_results":true},{"nct_id":"NCT04792489","title":"DALY II USA/ MB-CART2019.1 for DLBCL","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":248,"lead_sponsor_name":"Miltenyi Biomedicine GmbH","has_results":false},{"nct_id":"NCT05130489","title":"CAR T Cell Therapy Related Cardiovascular Outcomes","phase":"","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"University College London Hospitals","has_results":false},{"nct_id":"NCT04186520","title":"CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Medical College of Wisconsin","has_results":false},{"nct_id":"NCT07473167","title":"Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":98,"lead_sponsor_name":"TICAROS Co., Ltd.","has_results":false},{"nct_id":"NCT04600947","title":"Study of LP002 for the Treatment of Patients With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":69,"lead_sponsor_name":"Taizhou HoudeAoke Biomedical Co., Ltd.","has_results":false},{"nct_id":"NCT04875195","title":"A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT06486051","title":"A Study of WZTL-002 CAR T-cells for Adults With Relapsed Large B-cell Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Malaghan Institute of Medical Research","has_results":false},{"nct_id":"NCT06464861","title":"Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":52,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT06024694","title":"Primary Mediastinal Large B-cell Lymphoma With CNS Involvement","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":45,"lead_sponsor_name":"IRCCS San Raffaele","has_results":false},{"nct_id":"NCT05934448","title":"Pembro Plus CAR T-cell Therapy in R/R in PMBCL","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":35,"lead_sponsor_name":"Jennifer Crombie, MD","has_results":false},{"nct_id":"NCT05583149","title":"Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":28,"lead_sponsor_name":"Patrick C. Johnson, MD","has_results":true},{"nct_id":"NCT06208735","title":"CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"British Columbia Cancer Agency","has_results":false},{"nct_id":"NCT06026319","title":"CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"Marcela V. Maus, M.D.,Ph.D.","has_results":false},{"nct_id":"NCT07168486","title":"CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas","phase":"PHASE1","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":15,"lead_sponsor_name":"University of Maryland, Baltimore","has_results":false},{"nct_id":"NCT04002622","title":"Study of TQB2450 Injection in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","has_results":false},{"nct_id":"NCT05733650","title":"Expanded Access Program for Epcoritamab","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"Genmab","has_results":false}],"total":20},"guidelines":[],"source":"Drug Landscape verified database"}